Madrigal Pharmaceuticals Inc
Open
SectorGezondheidszorg
513 1.18
Overzicht
Wijziging aandelenprijs
24u
Min
503.59
Max
521.04
Inkomsten | -36M -94M |
|---|---|
Verkoop | -9.7M 311M |
EPS | -1.38 |
Winstmarge | -30.318 |
Werknemers | 915 |
EBITDA | -36M -86M |
Aanbevelingen | Strong Buy |
|---|---|
12 Maanden Prognose | +28.29% upside |
Volgende Winsten | 4 aug 2026 |
|---|
Marktkapitalisatie | -481M 11B |
|---|---|
Vorige openingsprijs | 511.82 |
Vorige sluitingsprijs | 513 |
Nieuwssentiment
By Acuity
56%
44%
263 / 342 Rangschikking in Healthcare
Madrigal Pharmaceuticals Inc Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Over Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
